ERBB2 and triple-negative breast carcinoma: Yet, forms such as the triple-negative breast cancer (TNBC, estrogen-, progesterone- and HER-2-negative (ER−,PR−,HER2−)), are exceedingly difficult to medicate because of the disease’s complexity and absence of distinct molecular targets [59].